Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PORTLAND, Ore., Aug. 21, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the European Patent Office notified the Company of an intention to grant a Pharmaceutical Use Patent for NeuVax™ (nelipepimut-S). The patent covers the use of NeuVax as a vaccine for the prevention of relapse in breast cancer patients with an immunochemistry (IHC) rating of 1+ or 2+ for HER2/neu protein expression and a fluorescence in situ hybridization (FISH) rating of less than 2.0 for HER2/neu gene expression. The patent protection is afforded in all of the European countries and will expire in April 2028.
Help employers find you! Check out all the jobs and post your resume.